FDA Grants Accelerated Approval to GSK's Nelkarmi for ALK-Positive Lung Cancer
The once-daily pill is cleared for adults who have already tried other targeted drugs, and the approval came ahead of the agency's original target date.
Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources
Brief
Regulators granted conditional approval on Nov. 17, 2026, to Nelkarmi, a daily pill from…
More reporting and context continue here.
The complete story is available with Premium.
Read the facts, open questions and supporting sources.
Continue reading with NewsPlain Premium.
Keep reading with NewsPlain Premium
Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.
5 confirmed facts, 1 open question and 2 sources behind this story.